WallStreetZenWallStreetZen

NASDAQ: DTIL
Precision Biosciences Inc Stock

$0.73-0.03 (-3.95%)
Updated Jun 9, 2023
DTIL Price
$0.73
Fair Value Price
$2.44
Market Cap
$83.30M
52 Week Low
$0.68
52 Week High
$2.13
P/E
-0.64x
P/B
2.07x
P/S
2.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$30.56M
Earnings
-$108.53M
Gross Margin
100%
Operating Margin
-349.92%
Profit Margin
-355.1%
Debt to Equity
4.09
Operating Cash Flow
-$48M
Beta
1.53
Next Earnings
Aug 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A

DTIL Overview

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DTIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DTIL ($0.73) is undervalued by 70.03% relative to our estimate of its Fair Value price of $2.44 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DTIL ($0.73) is significantly undervalued by 70.03% relative to our estimate of its Fair Value price of $2.44 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
DTIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DTIL due diligence checks available for Premium users.

Be the first to know about important DTIL news, forecast changes, insider trades & much more!

DTIL News

Valuation

DTIL fair value

Fair Value of DTIL stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$2.44
Undervalued by
70.11%
DTIL ($0.73) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DTIL ($0.73) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DTIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DTIL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.64x
Industry
11.33x
Market
52.94x

DTIL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.07x
Industry
5.2x
DTIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DTIL's financial health

Profit margin

Revenue
$8.8M
Net Income
-$25.1M
Profit Margin
-285.4%
DTIL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DTIL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$204.5M
Liabilities
$164.3M
Debt to equity
4.09
DTIL's short-term assets ($169.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DTIL's short-term assets ($169.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DTIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$31.5M
Investing
-$721.0k
Financing
$741.0k
DTIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DTIL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DTIL$83.30M-3.17%-0.64x2.07x
VTVT$83.87M-0.25%-3.82x-4.37x
DARE$84.56M-0.51%-2.72x17.01x
DMAC$84.57M-2.79%-5.32x3.13x
CLGN$84.70M-0.67%-4.93x2.83x

Precision Biosciences Stock FAQ

What is Precision Biosciences's quote symbol?

(NASDAQ: DTIL) Precision Biosciences trades on the NASDAQ under the ticker symbol DTIL. Precision Biosciences stock quotes can also be displayed as NASDAQ: DTIL.

If you're new to stock investing, here's how to buy Precision Biosciences stock.

What is the 52 week high and low for Precision Biosciences (NASDAQ: DTIL)?

(NASDAQ: DTIL) Precision Biosciences's 52-week high was $2.13, and its 52-week low was $0.68. It is currently -65.55% from its 52-week high and 7.33% from its 52-week low.

How much is Precision Biosciences stock worth today?

(NASDAQ: DTIL) Precision Biosciences currently has 113,793,338 outstanding shares. With Precision Biosciences stock trading at $0.73 per share, the total value of Precision Biosciences stock (market capitalization) is $83.30M.

Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been -95.8%, for an annualized return of -54.74% (not including any dividends or dividend reinvestments).

How much is Precision Biosciences's stock price per share?

(NASDAQ: DTIL) Precision Biosciences stock price per share is $0.73 today (as of Jun 9, 2023).

What is Precision Biosciences's Market Cap?

(NASDAQ: DTIL) Precision Biosciences's market cap is $83.30M, as of Jun 10, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Precision Biosciences's market cap is calculated by multiplying DTIL's current stock price of $0.73 by DTIL's total outstanding shares of 113,793,338.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.